

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

**RECORD DATE AND WITHHOLDING TAX RATE
IN CONNECTION WITH
THE PAYMENT OF 2025 FINAL DIVIDEND**

Sisram Medical Ltd (the “**Company**”) refers to the announcement issued by it dated 23 March 2026 in respect of the final results of the Company and its subsidiaries for the year ended 31 December 2025 (the “**Announcement**”). As disclosed in the Announcement, the Board has resolved to declare a final dividend of HK\$0.095 (inclusive of tax) per share for the year ended 31 December 2025 (the “**2025 Final Dividend**”). Unless otherwise stated, the terms used herein shall have the same meanings as defined in the Announcement.

The Board is pleased to announce that the 2025 Final Dividend will be paid on or around 9 September 2026 to the shareholders of the Company (the “**Shareholders**”) whose names appear on the register of members of the Company at the close of business on 27 August 2026. In order to be entitled to the 2025 Final Dividend, unregistered holders of shares of the Company should ensure all transfer documents accompanied by the relevant share certificates must be lodged with the Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17th Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, for registration not later than 4:30 p.m. on 27 August 2026.

Pursuant to Israeli Tax Ordinance, and based on the tax regime which applies to the Company, Shareholders are subject to a withholding tax of 20% on the 2025 Final Dividend. Such tax on the 2025 Final Dividend will be withheld at source by the Company, unless a Shareholder applies to the Israel Tax Authority and obtains an approval that it is entitled to a reduced tax rate under an applicable tax treaty between Israel and the Shareholder’s country of residence.

A Shareholder who is entitled to a reduced tax rate under an applicable tax treaty between Israel and the Shareholder’s country of residence, but had not obtained an approval from the Israel Tax Authority prior to a payment of a dividend, may apply for a tax refund by submitting a tax report to the Israel Tax Authority (Form 1301 for individuals and Form 1214 for companies) together with the relevant documents, such as identity document, tax residency document, certificate of incorporation and confirmation of the taxes withheld. The Company will apply to the Israel Tax Authority for such confirmation of the taxes withheld after the payment of the 2025 Final Dividend. Shareholders can contact the Company to obtain a copy of such confirmation through various communication channels shown on the official website of the Company at www.sisram-medical.com. In the tax report, the Shareholder is required to report all his income originating in Israel (and if such Shareholder is an Israeli tax resident, he

is required to report all worldwide income as well). The forms and details of how to apply for a tax refund can be obtained from the website of the Israel Tax Authority at www.taxes.gov.il. The application for a tax refund may be submitted to the Israel Tax Authority for a period of six years from the end of the year in which such dividend was distributed.

With respect to Shareholders who are resident in Hong Kong, there is currently no tax treaty between Israel and Hong Kong that gives rise to any tax benefits on the receipt of 2025 Final Dividend from the Company.

Shareholders are advised to seek their own independent professional tax advice.

On behalf of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Lior Moshe DAYAN
Chairman

Hong Kong, 13 August 2026

As at the date of this announcement, the Board of the Company comprises Mr. Lior Moshe DAYAN and Mr. Jiahong LI as executive directors; Mr. Yi LIU, Ms. Rongli FENG and Ms. Caroline Xiaokui JIN as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*